Fosfomycin Clinical Uses
Fosfomycin is primarily indicated as first-line treatment for uncomplicated cystitis in women as a single 3-gram oral dose, and intravenously for severe infections caused by multidrug-resistant organisms when used in combination therapy. 1
Primary Indication: Uncomplicated Cystitis
Oral fosfomycin trometamol (3 grams single dose) is recommended as first-line therapy specifically for uncomplicated cystitis in women. 1 The 2024 European Association of Urology guidelines explicitly list it as first-line treatment alongside nitrofurantoin and pivmecillinam. This recommendation is based on:
- Single-dose convenience enhancing patient compliance
- Achieves urinary concentrations of 706 mcg/mL within 2-4 hours, maintaining levels >100 mcg/mL for 26 hours 2
- Clinical success rate of 77% at 5-11 days post-therapy 2
- Can be taken without regard to food 2
Critical caveat: Fosfomycin is not recommended for pyelonephritis - the 2024 JAMA guidelines state there is insufficient evidence for oral fosfomycin in treating pyelonephritis, though IV formulations may be reasonable in some countries 3. This is a common prescribing error to avoid.
Secondary Indications
Multidrug-Resistant Infections (IV Formulation)
Intravenous fosfomycin serves as combination therapy for severe infections caused by MDR/XDR organisms, including:
- Bacteremia/sepsis (23.6% of cases in largest real-world study) 4
- Hospital-acquired/ventilator-associated pneumonia (11% of cases) 4
- Bone and joint infections (17.4% of cases) 4
- CNS infections/meningitis (7.8% of cases) 4
- Infective endocarditis (6.4% of cases) 4
The FORTRESS study demonstrated 75.3% clinical success with IV fosfomycin in combination therapy, including 78% success against MDR pathogens and 81.8% against carbapenem-resistant organisms 4. Fosfomycin was used in combination therapy in 90.2% of cases, most commonly with ceftazidime/avibactam (35%), meropenem (17%), or colistin (14%) 5.
Prostate-Related Infections
Fosfomycin has two distinct roles in prostate care:
Prophylaxis for transrectal prostate biopsy - International consensus supports fosfomycin as preferred antimicrobial prophylaxis due to low resistance rates, good safety profile, and adequate prostate tissue concentrations 6
Treatment of bacterial prostatitis - Oral fosfomycin may be considered for acute and chronic bacterial prostatitis, particularly with ESBL-producing E. coli, though this represents off-label use requiring further validation 7
Asymptomatic Bacteriuria in Kidney Transplant
Oral fosfomycin achieved microbiological cure in approximately 60% of post-kidney transplant asymptomatic bacteriuria cases, including 57.7% of MDR episodes, with no severe adverse events 8. However, previous UTI and salvage therapy use predicted failure, so reserve for first-line treatment when indicated.
Pathogen Coverage
Active against:
- E. coli (most common, 79% eradication rate) 2
- Enterococcus faecalis (100% eradication in small samples) 2
- Staphylococcus aureus including MRSA (31.4% of IV cases) 4
- Klebsiella species including carbapenem-resistant strains 4
- Other Enterobacterales 2
Key advantage: Generally no cross-resistance with beta-lactams or aminoglycosides due to unique mechanism (inhibits MurA enzyme in cell wall synthesis) 2
Dosing Specifics
- Oral (uncomplicated cystitis): 3 grams single dose 1
- IV (severe infections): Median 15 g/day in divided doses, always in combination 4
- Renal adjustment required: Half-life increases from 11 to 50 hours with declining renal function 2
Safety Profile
Well-tolerated overall:
- Most common adverse effects: diarrhea (9%), vaginitis (5.5%), nausea (4.1%), headache (3.9%) 2
- Electrolyte disturbances occur in 2.6% with IV formulation (most frequent concern) 5
- Gastrointestinal symptoms rare with IV use (2.9%) 5
- Pregnancy Category B 9
Important limitation: Resistance development occurs in 3.4% during monotherapy, which is why IV fosfomycin should virtually always be used in combination 10.